Genmab — April 2017
-
-
God morgen.
-
Norsk cancerselskab rejser 345 mio i børsnotering
Et norsk biotekselskab, der udvikler lægemidler mod kræft i blodet, er blevet børsnoteret i Oslo og har ved den lejlighed rejst, hvad der svarer til 345 mio. kr.
(medwatch.dk)
-
Our data further show that Dara activates but does not induce apoptosis in CD38(-) NK cells. Thus, we hypothesize that the combination of Dara and CD38(-) CS1-CAR NK cells can show a synergistic effect on tumor eradication and prevention of MM relapse. Our data indeed demonstrated that the combination of CS1 CAR NK cells with CD38(-) NK cells but not with CD38+ NK cells shows a synergistic effect to eradicate MM cells
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind